Development of Next-Generation HER2-Targeted ADC Candidates Employing NAMPT Inhibitor Payloads to Overcome Limitations of Current Therapies

Samjin Pharmaceutical

SAMJIN PHARM.

ONCOLOGY | **Candidate**

Product Type	Antibody
Indication	HER2+ solid cancers (HER2-ADC Refractory/relapsed HER2+/low breast cancer, gastric cancer, and HER2m NSCLC)
Target	HER2
MoA(Mechanism of Action)	Binding to cell surface antigen → Receptor-mediated endocytosis → Lysosomal degradation → Active payload release → Cell death
Competitiveness	First In Class NAMPTi-ADC • a Novel NAMPT inhibitor payload, offering a new mechanism of action that selectively targets cancer cells and achieves high efficacy with low toxicity by depleting NAD+ in tumor cells. • demonstrates superior anti-tumor efficacy and sustained tumor complete regression in HER2-positive cancer xenograft models compared to Enhertu. • maintains potent and durable anti-tumor activity against Enhertu resistant/relapse xenograft models. • provides effective treatment options beyond existing HER2-targeted ADCs.
Development Stage	Candidate
Route of Administration	Parenteral-Intravenous